Press Release Dec 04 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the receipt of an Establishment Inspection Report from the USFDA for its injectable facility in Jarod. The report classifies the facility as Voluntary Action Indicated following a GMP follow-up inspection conducted earlier. This disclosure is made in accordance with regulatory requirements for transparency to investors and exchange members.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 27 2025
- Press Release Nov 26 2025
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
- Press Release Nov 25 2025
- Press Release Nov 14 2025
Later from Zydus Lifesciences
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
- Press Release Dec 09 2025
- Press Release Dec 10 2025
- Press Release Dec 15 2025
- Zydus Lifesciences Limited Press Release Dec 19 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences